Literature DB >> 22410781

MiR-520h-mediated FOXC2 regulation is critical for inhibition of lung cancer progression by resveratrol.

Y-H Yu1, H-A Chen, P-S Chen, Y-J Cheng, W-H Hsu, Y-W Chang, Y-H Chen, Y Jan, M Hsiao, T-Y Chang, Y-H Liu, Y-M Jeng, C-H Wu, M-T Huang, Y-H Su, M-C Hung, M-H Chien, C-Y Chen, M-L Kuo, J-L Su.   

Abstract

Resveratrol, a phytochemical found in various plants and Chinese herbs, is associated with multiple tumor-suppressing activities, has been tested in clinical trials. However, the molecular mechanisms involved in resveratrol-mediated tumor suppressing activities are not yet completely defined. Here, we showed that treatment with resveratrol inhibited cell mobility through induction of the mesenchymal-epithelial transition (MET) in lung cancer cells. We also found that downregulation of FOXC2 (forkhead box C2) is critical for resveratrol-mediated suppression of tumor metastasis in an in vitro and in vivo models. We also identified a signal cascade, namely, resveratrol-∣miRNA-520h-∣PP2A/C-∣Akt → NF-κB → FOXC2, in which resveratrol inhibited the expression of FOXC2 through regulation of miRNA-520h-mediated signal cascade. This study identified a new miRNA-520h-related signal cascade involved in resveratrol-mediated tumor suppression activity and provide the clinical significances of miR-520h, PP2A/C and FOXC2 in lung cancer patients. Our results indicated a functional link between resveratrol-mediated miRNA-520h regulation and tumor suppressing ability, and provide a new insight into the role of resveratrol-induced molecular and epigenetic regulations in tumor suppression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22410781     DOI: 10.1038/onc.2012.74

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  56 in total

1.  3,4',5-trans-Trimethoxystilbene; a natural analogue of resveratrol with enhanced anticancer potency.

Authors:  Fahad S Aldawsari; Carlos A Velázquez-Martínez
Journal:  Invest New Drugs       Date:  2015-02-28       Impact factor: 3.850

Review 2.  MicroRNAs mediate therapeutic and preventive effects of natural agents in breast cancer.

Authors:  Zhipin Liang; Yaguang Xi
Journal:  Chin J Nat Med       Date:  2016-12

Review 3.  MicroRNA: master controllers of intracellular signaling pathways.

Authors:  Pak-Yin Lui; Dong-Yan Jin; Nigel J Stevenson
Journal:  Cell Mol Life Sci       Date:  2015-06-10       Impact factor: 9.261

Review 4.  An overview of epigenetics in Chinese medicine researches.

Authors:  Xue-Qing Hu; Shi-Bing Su
Journal:  Chin J Integr Med       Date:  2016-12-20       Impact factor: 1.978

5.  Resveratrol (3, 5, 4'-Trihydroxy-trans-Stilbene) Attenuates a Mouse Model of Multiple Sclerosis by Altering the miR-124/Sphingosine Kinase 1 Axis in Encephalitogenic T Cells in the Brain.

Authors:  K Alexa Orr Gandy; Jiajia Zhang; Prakash Nagarkatti; Mitzi Nagarkatti
Journal:  J Neuroimmune Pharmacol       Date:  2019-04-02       Impact factor: 4.147

6.  Resveratrol inhibits Erk1/2-mediated adhesion of cancer cells via activating PP2A-PTEN signaling network.

Authors:  Xin Chen; Xiaoyu Hu; Yue Li; Cuilan Zhu; Xiaoqing Dong; Ruijie Zhang; Jing Ma; Shile Huang; Long Chen
Journal:  J Cell Physiol       Date:  2018-08-01       Impact factor: 6.384

7.  FOXC2 promotes colorectal cancer metastasis by directly targeting MET.

Authors:  Y-M Cui; H-L Jiao; Y-P Ye; C-M Chen; J-X Wang; N Tang; T-T Li; J Lin; L Qi; P Wu; S-Y Wang; M-R He; L Liang; X-W Bian; W-T Liao; Y-Q Ding
Journal:  Oncogene       Date:  2014-11-10       Impact factor: 9.867

8.  Micro-RNAs associated with the evolution of ovarian cancer cisplatin resistance.

Authors:  Bernadette M Boac; Yin Xiong; Douglas C Marchion; Forough Abbasi; Stephen H Bush; Ingrid J Ramirez; Beman R Khulpateea; E Clair McClung; Amy L Berry; Nadim Bou Zgheib; Hye Sook Chon; Mian M Shahzad; Patricia L Judson; Robert M Wenham; Sachin M Apte; Anders E Berglund; Anthony M Magliocco; Johnathan M Lancaster
Journal:  Gynecol Oncol       Date:  2015-12-28       Impact factor: 5.482

9.  NF-κB-driven suppression of FOXO3a contributes to EGFR mutation-independent gefitinib resistance.

Authors:  Ching-Feng Chiu; Yi-Wen Chang; Kuang-Tai Kuo; Yu-Shiuan Shen; Chien-Ying Liu; Yang-Hao Yu; Ching-Chia Cheng; Kang-Yun Lee; Feng-Chi Chen; Min-Kung Hsu; Tsang-Chih Kuo; Jui-Ti Ma; Jen-Liang Su
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-18       Impact factor: 11.205

10.  GD3 synthase regulates epithelial-mesenchymal transition and metastasis in breast cancer.

Authors:  T R Sarkar; V L Battula; S J Werden; G V Vijay; E Q Ramirez-Peña; J H Taube; J T Chang; N Miura; W Porter; N Sphyris; M Andreeff; S A Mani
Journal:  Oncogene       Date:  2014-08-11       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.